Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Operating Expenses (2016 - 2025)

United Therapeutics (UTHR) has disclosed Operating Expenses for 17 consecutive years, with $433.5 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 14.62% to $433.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 billion through Dec 2025, up 12.65% year-over-year, with the annual reading at $1.7 billion for FY2025, 12.65% up from the prior year.
  • Operating Expenses hit $433.5 million in Q4 2025 for United Therapeutics, up from $411.0 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $443.9 million in Q1 2021 to a low of $173.9 million in Q1 2022.
  • Historically, Operating Expenses has averaged $321.0 million across 5 years, with a median of $318.6 million in 2022.
  • Biggest five-year swings in Operating Expenses: surged 134.12% in 2021 and later crashed 60.82% in 2022.
  • Year by year, Operating Expenses stood at $245.4 million in 2021, then rose by 28.73% to $315.9 million in 2022, then rose by 12.25% to $354.6 million in 2023, then increased by 6.66% to $378.2 million in 2024, then increased by 14.62% to $433.5 million in 2025.
  • Business Quant data shows Operating Expenses for UTHR at $433.5 million in Q4 2025, $411.0 million in Q3 2025, and $434.1 million in Q2 2025.